Dear Colleagues,

All of us have been working hard to keep up with the rapidly changing information distributed through email, television and social media. As a way to keep the channels of communication open and offer a concise list of resources, the GOG Foundation Communications Committee is sending the following recommendations for managing patients enrolled on clinical trials.

**GUIDELINES**

*Patient safety is always a primary concern. Patient clinical trial enrollment, monitoring visits, lab draws will vary depending on region, local government and institutional restrictions. Some sites may place a hold on new enrollment while others are able to continue to enroll new patients and open new studies.*

*During this Pandemic it may not be possible to always maintain clinical trial integrity. Therefore continue to document protocol deviations.*

Please refer to the links below (also available on our [website](#)) from the FDA, The Cancer Letter and NIH NCI CTEP for more specific information. The situation is evolving from day to day and we will all need to be fluid and adapt to the changing environment and health care resources. Please feel free to reach out to us directly with any related questions at [info@gog.org](mailto:info@gog.org). We will continue to keep everyone updated with new recommendations.

- A message to GOG Foundation Investigators from Dr. Copeland
- [A message to GOG Partners Industry Colleagues from Dr. Copeland](#)
- [A Message from the Biopathology Center](#)
- [FDA Guidance for Industry, Investigators, and IRBs](#)
- [Interim Guidance for Patients on Clinical Trials Supported by CTEP and NCORP](#)
- [Additional Guidance Regarding Alternative Procedures for Clinical Trials Supported by CTEP and NCORP Affected by the Spread of the Novel Coronavirus](#)
- [The Cancer Letter](#)
- [Surgical Procedures: SGO/ACOG Position Statement](#)

Sincerely,

Larry J. Copeland, M.D.
President
The GOG Foundation, Inc.